Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Avadel Pharmaceuticals' Board Of Directors Has Determined That The Unsolicited Proposal From H. Lundbeck Constitutes A "Company Superior Proposal" Over The Existing Transaction Agreement With Alkermes

Author: Benzinga Newsdesk | November 17, 2025 05:47am

Lundbeck Proposal Values Avadel at up to $23.00 per Ordinary Share, a Total of Approximately $2.4 billion
Pursuant to Alkermes Transaction Agreement, Avadel and Alkermes May Negotiate Potential Adjustments to Existing Transaction for 5 Business Days
Alkermes Transaction Agreement Remains in Effect; No Action Required by Avadel Shareholders

Posted In: ALKS AVDL